Denaturing high-performance liquid chromatography (DHPLC) as a reliable high-throughput prescreening method for aberrant promoter methylation in cancer

Human Mutation

Volumn 23, Issue 6, 2004, Pages 612-620

  Betz, Beate ^a   Florl, Andrea R ^a   Seifert, Hans Helge ^a   Dall, Peter ^a   Schulz, Wolfgang A ^a   Niederacher, Dieter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cancer; CDKN2A; DHPLC; Methylation; p16INK4A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLIN DEPENDENT KINASE 2; PROTEIN P16;

ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER; CPG ISLAND; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA METHYLATION; GENE SILENCING; HETEROZYGOSITY; HIGH THROUGHPUT SCREENING; HUMAN; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC SCREENING; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 2642523833     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20033     Document Type: Article

References (33)

1. An HX, Niederacher D, Picard F, van Roeyen C, Bender HG, Beckmann MW. 1996. Frequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer. Genes Chromosomes Cancer 17:14-20.
2. Baud E, Catilinia P, Bignon, YJ. 1999. p16 involvement in primary bladder tumors: analysis of deletions and mutation. Int J Oncol 14:441-445.
3. Baumer A, Wiedemann U, Hergersberg M, Schinzel A. 2001. A novel MSP/ DHPLC method fort the investigation of the methylation status of imprinted genes enables the molecular detection of low cell mosaicims. Hum Mutat 17:423-430.
4. Baumer A. 2002. Analysis of the methylation status of imprinted genes based on methylation-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography. Methods 27:139-143.
5. Bedford MT, van Helden PD. 1990. A method to analyze allele-specific methylation. Biotechniques 9:744-748.
6. Brenner AJ, Paladugu A, Wang H, Olopade OI, Dreyling MH, Aldaz CM. 1996. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res 2:1993-1998.
7. Couvert P, Poirier K, Carrié A, Chalas C, Jouannet P, Beldjord C, Bienvenu T, Chelly J, Kerjean A. 2003. DHPLC-based method for DNA methylation analysis of differential methylated regions from imprinted genes. Biotechniques 34:356-362.
8. Florl AR, Franke KH, Niederacher D, Gerharz C-D, Seifert H-H, Schulz WA. 2000. DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab Invest 80:1513-1522.
9. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89:1827-1831.
10. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, Issa JP. 2002. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8:2217-2224.
11. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG. 2002. DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet 111:115-127.
12. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson N, Sidransky D, Baylin SB. 1995. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530.
13. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826.
14. Huber CH. 1998. Micropellicular stationary phases for high-performance liquid chromatography of double stranded DNA. J Chromatogr 806:3-30.
15. INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 6:2777-2787.
16. Hunter T, Pines J. 1994. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 79:573-582.
17. Jones PA, Baylin SB. 2002. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428.
18. Kai M, Arakawa H, Sugimoto Y, Murata Y, Ogawa M, Nakamura Y. 1995. Infrequent somatic mutation of the MTS1 gene in primary bladder carcinomas. Jpn J Cancer Res 86:249-251.
19. Keen AJ, Knowles MA. 1994. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9:2083-2088.
20. Lehmann U, Länger F, Feist H, Glöckner S, Hasemeier B, Kreipe H. 2002. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Path 160:605-612.
21. Lilischkis R, Kneitz H, Lehmann U, Kreipe H. 2000. Positive display of methylation sites: a novel method fort he detection of promoter methylation. Diagn Mol Pathol 9:165-171.
22. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 1995. 5′-CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686-692.
23. INK4a tumor suppressor gene 5′-CpG island in breast cancer. Cancer Lett 163:59-69.
24. Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ. 1995. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene 11:1211-1216.
25. Pagliuca A, Gallo P, Lania L. 2000. Differential Role for Sp1/Sp3 transcription factors in the regulation of the promoter activity of multiple cyclin-dependent kinase inhibitor genes. J Cell Biochem 76:360-367.
26. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. 1995. Alternative reading frames of the INK4A tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
27. Quesnel B, Fenaux P, Philippe N, Fournier J, Bonneterre J, Preudhomme C, Peyrat JP. 1995. Analysis of p16 gene deletion and point mutation in breast carcinoma. Br J Cancer 72:351-353.
28. Ruas M, Peters G. 1998. The p16INK4A/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378: F115-F177.
29. Serrano M, Hannon GJ, Beach DA. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclinD/CDK4. Nature 366:704-707.
30. Silva J, Silva JM, Dominguez G, Garcia JM, Cantos B, Rodriguez R, Larrondo FJ, Provencio M, Espana P, Bonilla F. 2003. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Path 199:289-297.
31. Uhlmann K, Brinckmann A, Toliat MR, Ritter H, Nurnberg P. 2002. Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis 23:4072-4079.
32. Warnecke PM, Stirzaker C, Song J, Grunau C Melki JR, Clark SJ. 2002. Identification and resolution of artefacts in bisulfite sequencing. Methods 27:101-107.
33. Xu L, Sgroi D, Sterner CJ, Beauchamp RL, Pinney DM, Keel S, Ueki K, Rutter JL, Buckler AJ, Louis DN, Gusella JF, Ramesh V. 1994. Mutational analysis of CDKN2 (MTS1/p16INK4) in human breast carcinomas. Cancer Res 54:5262-5264.